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Abstract 
The underlying cause of Duchenne and Becker muscular dystrophies is a lack of 
functional dystrophin, a large multidomain protein. Dystrophin is normally expressed in 
muscle, where it links the extracellular matrix to the cortical actin cytoskeleton via a 
complex of associated proteins. Dystrophin, and its autosomal homologue utrophin, 
connect with the actin cytoskeleton through two F-actin binding domains, including an 
N-terminal “actinin-type” actin binding domain (ABD). 
In addition to dystrophin and utrophin, actinin-type ABDs are found in a large 
number of proteins. Nonetheless, the actin binding mechanism remains poorly 
understood: x-ray crystallography and electron microscopy have produced conflicting 
models. Electron paramagnetic resonance (EPR) spectroscopy, especially double 
electron-electron resonance (DEER), can be used to distinguish between these models or 
to build new models. In this thesis, I present data from DEER experiments which suggest 
that actinin-type ABDs of dystrophin and utrophin adopt unexpected conformations in 
solution. 
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Chapter 1 | Dystrophin, Utrophin, and Duchenne/Becker Muscular Dystrophy 
1.1 | Dystrophin is a large structural protein required for muscle cell integrity.  
 Dystrophin is a large (427 kDa) multidomain 
protein expressed in muscle, where it localizes to 
costameres (1). At its N-terminus, the dystrophin 
protein contains the first of two actin binding 
domains (DysABD1) (Fig. 1A). DysABD1 is 
followed by a rod-like region of 24 spectrin type 
repeats, within which are four hinge regions. Spectrin 
repeats 11 through 17 constitute the second actin 
binding domain (DysABD2). Repeats within the rod 
domain also allow dystrophin to bind to microtubules 
(2). The rod is followed by a cysteine-rich domain and a C-terminal domain, which bind 
to -dystroglycan and -dystrobrevin, respectively (1, 3, 4).  
 -dystroglycan and -dystrobrevin are members of the dystrophin-glycoprotein 
complex, which is composed of sarcoplasmic, transmembrane, and extracellular proteins 
(3). The dystrophin-glycoprotein complex binds to intermediate filaments in the 
extracellular matrix. Dystrophin thus forms a physical link at costameres between the 
extracellular matrix and cortical actin, helping to stabilize the sarcolemma during 
contraction (5). 
 Stabilization of the sarcolemma by dystrophin is crucial for the maintenance of 
muscle cell integrity. Duchenne muscular dystrophy (DMD), a severe X-linked disorder, 
DystrophinA
ABD2ABD1 C-term
Cys rich
B Utrophin
ABD2ABD1 C-term
Cys rich  
Fig. 1. Dystrophin and Utrophin. (A) 
The N-terminal ABD1 of dystrophin is 
made up of two CH domains, connected 
to the 24 spectrin type repeat (STR) rod 
domain, followed by the Cys-rich and C-
terminal domains. STRs 11-17 act as an 
additional ABD. (B) Utrophin is similar; 
2 STRs are deleted and the ABD2 is 
contiguous with the ABD1. (1) 
  2 
results from mutations which caused either a loss of function in dystrophin or a reduction 
of dystrophin expression (6, 7). Although the precise molecular mechanisms are 
uncertain, in the absence of dystrophin the sarcolemma becomes vulnerable to damage 
during muscle contraction. Intracellular calcium is increased, and muscle undergoes 
continuous degeneration and regeneration, with increasing fibrosis (8-12). In humans, 
muscle weakness is typically observed around age 5, leading to diagnosis (13). Without 
the use of glucocorticoid corticosteroids, affected boys are wheelchair-bound by their 
teenage years, and die during their late teens or early twenties. Less severe mutations 
result in expression of a partially functional dystrophin, leading to Becker muscular 
dystrophy (BMD). The severity of the BMD phenotype is variable, but is generally 
similar to DMD, although often more mild (13, 14).  
 The actin binding property of dystrophin is fundamentally necessary to its function. 
An N-terminally truncated dystrophin isoform lacking DysABD1 only partially rescued 
the mdx mouse model of DMD, while in trans co-expression of N-terminal and C-
terminal dystrophin constructs failed to rescue both the mdx and dko mouse models of 
DMD (15, 16). These results demonstrate that each dystrophin molecule must directly 
interact with both cortical F-actin and the dystroglycan complex, making DysABD1 
especially important for dystrophin function.  
1.2 | Utrophin is an autosomal homologue of dystrophin. 
 Utrophin is an autosomal homologue of dystrophin which is expressed even in 
DMD/BMD patients (17-19). Expressed ubiquitously during embryonic development, 
utrophin then becomes restricted to the myotendinous and neuromuscular junctions in 
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adults. The 394 kDa utrophin protein is substantially similar to dystrophin: like 
dystrophin, utrophin contains an N-terminal ABD (UtrABD1), followed by a rod region 
composed of spectrin repeats, as well as  cysteine-rich and C-terminal domains which 
interact with the dystroglycan complex (Fig. 1B) (1, 4).  
 As in dystrophin, utrophin also has second actin binding region within the rod 
domain, although in utrophin the ABD2 is composed of repeats 1-10. Unlike dystrophin, 
utrophin does not recruit neuronal nitric oxide synthase to the sarcolemma, and does not 
bind microtubules (20, 21). Utrophin is also slightly smaller, lacking two spectrin repeats 
as compared to dystrophin (1).  
 The similarities between dystrophin and utrophin appear to be greater than their 
differences, since overexpression of utrophin rescues the mdx mouse (22). Utrophin-
based gene therapy strategies for DMD/BMD are therefore of major interest as an 
alternative to dystrophin-based strategies, especially following the failure of a 
dystrophin-based gene therapy trial due to an immune response targeting dystrophin (23-
25).  
1.3 | Understanding dystrophin and utrophin structure to design better therapies. 
 Pharmacological and non-pharmacological interventions have begun to change the 
natural history of DMD, leading to longer lifespans and improved quality of life (26). 
Nonetheless, treatment options remain limited, with pharmacological options restricted to 
glucocorticoid corticosteroids (i.e., prednisone, prednisolone, and deflazacort). 
Continuous glucocorticoid corticosteroid treatment merely delays disease progression, 
and is accompanied by strong side effects (27-29). DMD therefore remains a serious 
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disease for which new treatment options are continually sought (25, 30).  
 Since DMD and BMD are genetic diseases arising from mutations within a single 
gene, the most direct approach would be to complement the native gene with one 
encoding a functional dystrophin. Major efforts have therefore been dedicated to the 
development of gene therapy for DMD. To avoid problems arising from an immune 
response to dystrophin, utrophin has also been considered as a dystrophin replacement 
(25). 
 Adeno-associated viral vectors are commonly favored, but have a limited genomic 
capacity of ~5 kB. Since the dystrophin mRNA is ~14 kB, this has necessitated the 
creation of “micro” dystrophin and utrophin constructs (31). Such constructs draw 
inspiration from BMD patients who display relatively minor symptoms despite especially 
large deletions in the gene encoding dystrophin (32). Although gene therapy has proven 
difficult to translate into an approved clinical treatment, animal models have provided a 
proof of concept (22-24, 33).   
 Designing miniaturized dystrophin or utrophin constructs for use in gene therapy 
requires compromise with regard to gene size versus protein function. For instance, a 
dystrophin construct lacking the ABD2 will have a reduced affinity for actin, which may 
in turn reduce its therapeutic potential. With improved structural understanding of 
dystrophin and utrophin, it may be possible to engineer improved constructs which retain 
a greater proportion of their normal functional. With respect to actin binding, naturally 
occurring mutations which increase actin binding affinity have been observed in the ABD 
of -actinin (which is homologous to the ABD1 in dystrophin) (34-36). In a dystrophin 
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construct lacking the ABD2, such a mutation might prove beneficial rather than harmful. 
That is, if the actin binding mechanism of the ABD1 were understood, then it might be 
possible to tune the binding affinity of the dystrophin/utrophin ABD1 and improve the 
overall function of a micro dystrophin/utrophin construct. 
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Chapter 2 | Dystrophin and Utrophin Actin Binding Domain 1 
2.1 | Introduction 
 The N-terminal actin binding domains of dystrophin and utrophin (DysABD1 and 
UtrABD1), belong to 
the actinin-type family 
of actin binding 
domains. (37-39). 
Actinin-type ABDs are 
found in a wide variety 
of F-actin binding 
proteins, including α-actinin, β-spectrin, fimbrin, filamin, and plectin, in addition to 
utrophin and dystrophin. Isolated DysABD1 and UtrABD1 constructs bind F-actin with 
micromolar affinity; in combination with their respective ABD2s, they allow dystrophin 
and utrophin to bind to F-actin with sub-micromolar affinity (40-44).  
 Crystal structures have been determined for several actinin-type ABDs, including 
utrophin and dystrophin (45, 46). These structures show that actinin-type ABDs are 
themselves composed of a pair of tandem calponin homology domains (CH1 and CH2). 
Each CH domain is composed of a “sandwich” of 4 major α-helices connected by more 
variable minor α-helices and loops, with CH1 and CH2 connected by an α-helical linker. 
Despite the similarity between CH1 and CH2, CH1 is generally more similar to CH1 
from other actinin-type ABDs than to CH2 from the same domain, and vice versa (39). 
  The crystal structures of DysABD1 and UtrABD1 differ significantly from the 
CH1b CH1b CH1
CH2b
CH2a CH2
A B C
 
Fig. 2. X-ray Crystal Structure of DysABD1. DysABD1 crystallized as an 
antiparallel dimer, suggesting either an open conformation (D) or a closed 
conformation (E) similar that of -actinin (F). UtrABD1 (not shown) 
crystallized as a dimer similar to that of DysABD1 (45-47). 
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crystal structures of other actinin-type ABDs. Whereas ABDs from -actinin, plectin, 
and fimbrin crystallized as compact monomers in which the CH domains are folded back 
upon each other, dystrophin and utrophin have crystallized as dimers in which each 
protomer adopts a more extended conformation (Fig. 2A) (47-50). However, in these 
dimeric structures, CH1 and CH2 from opposite members of the dimer are closely 
apposed, resulting in a compact structure similar to that from α-actinin crystals via 
domain swapping (Fig. 2B, C).  
 The unusual dimeric crystal forms of UtrABD1 and DysABD1, combined with an 
inability to crystallize F-actin, created uncertainty as to how DysABD1 and UtrABD1 
might bind to actin. Subsequently, Galkin, et al. (51) published a model of the UtrABD1 
bound to F-actin reconstructed from electron micrographs. In this “open EM” model, 
UtrABD1 occupies an open conformation similar to, but more extended than, the 
protomer within the x-ray crystal dimer. However, Sutherland-Smith, et al. (52), also 
using electron microscopy, subsequently published models for both UtrABD1 and 
DysABD1 bound to actin in a closed conformation, similar to that seen by domain 
swapping within the x-ray crystal structures (“closed EM” models).  Therefore, electron 
microscopy has been unable to distinguish between the possible closed an open binding 
modes of DysABD1 and UtrABD1. 
 The distance between a given point on CH1 and a given point on CH2 is a 
distinguishing characteristic of each model; a short distance is predicted by the closed 
EM models, while the distance between the same points in the x-ray crystal protomer or 
in the open EM model of utrophin is greater. Lin, et al. (53) took advantage of this 
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property to determine the conformation 
of UtrABD1 free in solution and bound 
to F-actin using double electron-
electron resonance (DEER).  
 DEER is a pulsed electron 
paramagnetic resonance (EPR) 
technique capable of determining both 
distance distribution between two spin 
labels, if the distances are on the order 
of 2-8 nm (Fig. 3). Site directed spin 
labeling allows the placement of the 
thiol-reactive maleimide spin label (MSL) at selected residues within a protein which 
have been mutated to cysteine. Native cysteine residues, if any, are mutated to alanine or 
serine (54-57).  
 By mutating a single residue within each CH domain of UtrABD1 to cysteine and 
labeling with MSL, Lin, et al. (53) were able determine the distance between CH 
domains via DEER. In the absence of actin, UtrABD1 was found to exist in equilibrium 
between two states: one which agreed well with the distance expected of the crystal 
protomer, and a somewhat more extended state. Moreover, upon the addition of F-actin, 
the distance between CH1 and CH2 increased and was most consistent with the open EM 
model of Galkin, et al. (51). Importantly, no evidence of a short distance suggestive of a 
closed conformation was observed. 
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Fig. 3. DEER is sensitive to distance and disorder. A-
C: Two single Gaussian distributions (as of a doubly 
spin-labeled molecule in solution) which differ in amount 
of disorder were simulated with centers at 2 nm (A), 3 
nm (B), or 4 nm (C). The simulated DEER waveforms 
for these populations are shown in D-F, respectively. In 
all cases, the waveforms are sufficiently different to 
distinguish between both distance center and disorder.  
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 In order extend and confirm the conclusions reached by Lin, et al.(53), DysABD1 
and UtrABD1 were both labeled with MSL at novel sites, one per CH domain. DEER 
experiments were then carried out either in the absence of actin or in the presence of up 
to a four-fold molar excess of F-actin, and the distance distributions determined from the 
DEER waveforms.  
2.2 | Materials & Methods 
2.2.1 | Protein Purification and Spin Labeling 
 Plasmids encoding murine UtrABD1 (residues 1-261, UniProt O08614) and murine 
DysABD1 (residues 1-246, UniProt P11531) were provided to Roberto Dominguez and 
David Kast at the University of Pennsylvania. DEER constructs were then generated, 
expressed, and labeled at the University of Pennsylvania.  
 Constructs were generated as previously (58). UtrABD1 and DysABD1 were 
subcloned into pTYB11 (New England BioLabs), resulting in an N-terminal fusion of a 
chitin affinity tag and an intein domain. UtrABD1 constructs in which S54, T220, or both 
S54 and T220 were mutated to cysteine (S54C, T220C, S54C:T220C) were generated. To 
improve the stability of DysABD1, residues 2-8 were deleted and C9 was mutated to 
aspartic acid. DysABD1 constructs were then generated either by mutating D38 to 
cysteine and C205 to serine (for singly-labeled controls) or by only mutating D38 to 
cysteine (D38C:C205). All mutagenesis was carried out using a QuikChange II XL site-
directed mutagenesis kit (Strategene). 
 All constructs were expressed in Escherichia coli BL21(DE3) cells. As previously 
described, cells were re-suspended and lysed using a microfluidizer and the construct 
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purified on a chitin affinity column. The chitin tag was removed by inducing self-
cleavage of the intein, after which the constructs were further purified using a Superdex-
200 size exclusion column (GE Healthcare).  
 UtrABD1 and DysABD1 constructs were labeled with MSL [N-(1-Oxyl-2,2,6,6-
tetramethyl-4-piperidinyl)maleimide]. Labeled samples were exchanged into 50 mM Tris 
pH 7.5, 100 mM NaCl. Complete labeling was determined by mass spectrometry. 
Labeled proteins were then shipped on ice to the University of Minnesota, where samples 
for DEER were made immediately upon receipt. 
2.2.2 | Preparation of F-actin 
 Actin was prepared from acetone powder derived from rabbit skeletal muscle as 
described previously (59). Acetone powder was incubated for 30 minutes on ice in water 
pre-chilled to 4°C. The mixture was then filtered, and 30 mM KCl was added to the 
filtrate. Following 60 minutes incubation at room temperature the filtrate (containing the 
polymerized actin) was centrifuged either in a Beckman TLA100.3 rotor for 30 minutes 
at 80,000 rpm at 4°C (for small volumes) or in a Beckman Type Ti70.1 rotor for 60 
minutes at 50,000 rpm at 4°C (for larger volumes). The supernatant was discarded, and 
the pellet (containing the polymerized actin) was washed and then re-suspended in G-
buffer (5 mM Tris pH 7.5, 0.5 mM ATP, 0.2 mM CaCl2.) The G-actin was then clarified 
by centrifugation in a Beckman TLA100.3 rotor at 70,000 rpm for 10 minutes at 4°C. 
The amount of G-actin recovered was then determined by UV/Vis spectrophotometry 
based on an extinction coefficient at ε290=0.63 ml mg
-1
 cm
-1
. The actin was then re-
polymerized by adding 2 mM MgCl2 and incubating at room temperature for 30 minutes. 
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The F-actin was then pelleted by centrifugation in a Beckman TLA100.3 rotor at 80,000 
rpm for 30 minutes at 4°C, and the pelleted F-actin re-suspended to the desired 
concentration in F-buffer (25 mM Tris pH 8.0, 100 mM NaCl, 0.5 mM ATP, 2 mM 
MgCl2, 1 mM DTT).  
2.2.3 | DEER 
Sample Preparation: UtrABD1 S54C.MSL:T220C.MSL, UtrABD1 S54C.MSL, 
UtrABD1 T220C.MSL, DysABD1 D38C.MSL:C205.MSL, or DysABD1 D38C.MSL 
was mixed to 80 M with either a 0.5-fold, two-fold, or four-fold molar excess of F-actin 
in 25 mM Tris pH 8.0, 100 mM NaCl, 2 mM MgCl2, with 10% (v/v) glycerol. After 
mixing, samples were allowed to incubate on ice for 30 minutes. 15 L samples were 
then flash frozen in liquid nitrogen, and stored at -80°C. Actin-free samples were 
prepared similarly, except that additional F-buffer was used to maintain the correct 
volume.  
Data Acquisition and Analysis: DEER was performed on a Bruker EleXys E580 Q-band 
instrument cooled to 65K. DEER waveforms were analyzed using DEER Analysis 2008, 
an open-source software package for Matlab (60). 
Table 1. Labeling sites used and predicted C-C distances in nm.  
 Closed EM
 (52)
 Closed Crystal
1 (45, 46)
 Open Crystal
2 (45, 46)
 Open EM
 (51)
 
UtrABD1 
S54C T220C 
2.4 2.4 6.4 7.7 
DysABD1 
D38C C205 
2.4 2.2 6.8 - 
UtrABD1 and DysABD1 were labeled with MSL at the named residues. Distances between residues are 
measured from C to C in nm. 
1
Measured from protomer A to protomer B within the crystal dimer.  
2
Measured within a single protomer. 
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2.3 | Results 
2.3.1 | Utrophin ABD1 
 UtrABD1 was labeled with MSL at S54C and T220C. For this set of labeling sites, 
the closed EM model from Sutherland-Smith, et al. (52) predicts a C-C distance of 2.4 
nm, in accordance with the distance between opposite members of the dimer observed by 
x-ray crystallography (Table 1) (46). The x-ray protomer predicts a larger C-C 
distance of 6.4 nm, while the open EM model from Galkin, et al. (51) predicts a distance 
of 7.7 nm. The closed and open models should therefore be distinguishable by DEER, 
based on simulated spectra for each of these distances (Fig. 4).  
 Initial analysis of the DEER waveforms showed that, in the absence of actin, the 
distance between the labels at S54C and T220C fit best to a single Gaussian distribution 
centered at 3.7 nm (Fig. 5A). As F-actin was added in increasing amounts, a two 
Gaussian model fit best (Fig. 5B-H). At 0.5 mol actin/mol UtrABD1, the Gaussians were 
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Fig. 4. Simulated UtrABD1 DEER waveforms. Distances between residues 54 and 220 of UtrABD1 as 
measured from C-C for the closed EM structure (A), the x-ray crystal protomer (B), or the open EM 
structure (C), and simulated DEER waveforms (D). The difference between a short distance/closed 
structure and a long distance/open structure is readily apparent. (46, 51, 52) 
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centered at 3.4 nm and 4.6 nm. At 2 mol actin/mol UtrABD1, the two Gaussians were 
centered at 3.7 nm and 5.4 nm. At 4 mol actin/mol UtrABD1, the two Gaussians were 
centered at 4.1 nm and 5.9 nm. Notably, as the amount of F-actin added increased, the 
proportion of the population at the longer distance became more prominent.  
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Fig. 5. DEER waveforms for UtrABD1. UtrABD1 was labeled with MSL at residues 54 and 220, and 
DEER was performed without actin, at 0.5 mol actin/mol UtrABD1, 2 mol actin/mol UtrABD1, or 4 mol 
actin/mol UtrABD1. The corresponding distance distributions are shown below their respective spectra. 
Numbers represent the center of the Gaussian represented by the adjacent peak, in nm. A-H: Background 
correction was performed by allowing DEER Analysis 2008 to computationally fit the background with a 
homogenous model (“Homology Background”). J-Q: As in A-H, except that background correction was 
performed using functions derived from equivalent DEER experiments in which UtrABD1 was labeled at 
only residue 54 or only at residue 220.  
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 Taken together, this data suggested that in the absence of actin UtrABD1 adopts a 
conformation such that the distance between residues 54 and 220 is 3.7 nm. The data also 
suggested that the actin-bound UtrABD1 adopts a conformation such that the distance 
between these two residues is increased, though the long distance and amount of disorder 
made it difficult to determine the distance precisely. 
 To improve the fits and eliminate artifacts due to filamentous nature of F-actin, 
spectra were acquired from UtrABD1 labeled at a single cysteine (either S54C or T220C) 
mixed with F-actin. When these experimentally derived background spectra were used 
during the fitting process, a longer distance no longer appeared as F-actin was added. The 
spectra could largely be fit by a single Gaussian centered at about 3.7 nm, with a slight 
increase in distance to about 4.3 nm at high concentrations of F-actin (Fig. 5J-Q). This 
suggested that UtrABD1 adopts a relatively closed conformation when free in solution, 
though somewhat more extended and disordered than suggested by the crystal structure, 
and that the UtrABD1 rearranges upon binding to F-actin such that the distance between 
CH1 and CH2 is increased slightly. 
2.3.2 | Dystrophin ABD1 
 DysABD1 was labeled with MSL at D38C and C205. The C-C distance between 
these two residues is predicted to be 2.4 nm by the closed EM structure published by 
Sutherland-Smith, et al. (52). Likewise, the C-C distance between these two residues 
on opposite monomers within the x-ray crystal dimer is 2.2 nm (45). When measured 
between residues within a single monomer, the crystal predicts a distance of 6.8 nm 
(Table 1). There is no open EM model of DysABD1, the existence of an open EM 
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structure for UtrABD1 suggests that a similar conformation might be possible for 
DysABD1: that is, one which is similar to the crystal protomer but somewhat more 
extended. Importantly, there is a large difference between the distance predicted by 
closed and open models, so DEER should be able to distinguish between the two (Fig. 6). 
 Initial analysis of the DEER waveforms suggested that, in the absence of actin, the 
range of conformations adopted by DysABD1 is best fit a 2-Gaussian model with the 
bulk of the population (65%) centered at 2.5 nm, and a smaller subset at 3.5 nm (Fig. 7A, 
E). As F-actin was added to DysABD1, the observed distance distribution did not change 
substantially, even at a four-fold excess of actin (Fig. 7B-D, F-H).  
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Fig. 6. Simulated DysABD1 DEER waveforms. Distances between residues 38 
and 205 of DysABD1 as measured from C-C for the closed EM structure (A) 
and the x-ray crystal protomer (B). Simulated DEER waveforms for these distances 
(C) show that a short distance/closed structure and a long distance/open structure 
are readily distinguished. (45, 52) 
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 To improve the reliability of the fits, the DEER waveforms were re-analyzed using 
data from equivalent DEER experiments in which DysABD1 was labeled only at D38C 
to improve the background subtraction (Fig. 7J-Q). Unlike for UtrABD1, the more 
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Fig. 7. DEER waveforms for DysABD1. DysABD1 was labeled with MSL at residues 38 and 205, and 
DEER was performed without actin (A), at 0.5 mol actin/mol DysABD1 (B), 2 mol actin/mol DysABD1 
(C), or 4 mol actin/mol DysABD1 (D). The corresponding distance distributions (E-H) are shown below 
their respective spectra. Numbers represent the center of the Gaussian represented by the adjacent peak, in 
nm. A-H: background subtraction was performed by allowing DEER Analysis 2008 to computationally fit 
the background a homogenous model (“Homology Background”). J-Q: as in A-H, except that background 
subtraction was performed using functions derived from equivalent DEER experiments in which DysABD1 
was labeled at only residue 38.  
  17 
rigorous analysis did not substantially change the interpretation of the spectra. Both in the 
absence of actin and when mixed with F-actin up to a four-fold molar excess, the distance 
distributions again showed that DysABD1 adopts a conformation which can best be 
modeled as the sum of two overlapping Gaussians. The first Gaussian, accounting for 
approximately two thirds of the population, is centered at 2.5 nm and is relatively narrow, 
while a second broader Gaussian centered at 3.3-3.6 nm accounts for the remaining third 
of the population.      
 Notably, the 2.5 nm distance which represents the bulk of the population, agrees 
reasonably well with the 2.4 nm predicted by the closed EM model. This suggests that the 
bulk of the population adopts a closed conformation even while bound to actin, whereas a 
subset of the population occupies a more extended conformation.  
2.4 | Discussion 
2.4.1 | The utrophin ABD1 may adopt a novel conformation in solution. 
 Initial analysis of the DEER waveforms suggested that UtrABD1 adopts a 
relatively closed conformation while free in solution, albeit not as compact as predicted 
by the closed EM models. The same analysis suggested that when bound to actin, 
UtrABD1 adopts a more extended conformation (Fig. 5A-H).  
 However, a more rigorous analysis using experimentally derived spectra for 
background subtraction suggested that there is actually little change in the conformation 
of UtrABD1 upon the addition of F-actin (Fig. 5J-Q). Instead, UtrABD1 appears to 
remain in a conformation which is neither as compact as predicted by the closed EM 
model or the domain swapped x-ray crystal, nor as extended as predicted by the open EM 
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model. This suggests that UtrABD1, when in solution, occupies a conformation different 
from what had previously been predicted by either x-ray crystallography or electron 
microscopy. 
 In the previous work by Lin, et al. (53), UtrABD1 was labeled with MSL at V136C 
and L222C. Lin and colleagues determined that, when free in solution, UtrABD1 exists in 
equilibrium between two states, one of which agrees with the x-ray crystal monomer. 
UtrABD1 was also found to occupy a second more extended conformation. By adding F-
actin, Lin et al. (53) then determined that the UtrABD1 binds to actin filaments in an 
extended conformation corresponding to the open EM model. These conclusions are in 
strong contrast to those suggested by Fig. 5. 
 The discrepancy may be explained in several ways. In the simplest case, we might 
reject the data presented in Fig. 5 in favor of the data and conclusions presented by Lin, 
et al (53). Of the two sets of experiments, theirs was the better controlled: Lin, et al. 
present supplemental data showing that neither mutagenesis of their labeling sites to 
cysteine, nor labeling with MSL, altered actin binding function based on an actin co-
sedimentation assay. Circular dichroism was also used to show that site directed spin 
labeling did not disturb UtrABD1 secondary structure. Equivalent controls have not yet 
been carried out for UtrABD1 labeled at S54C/T220C. It may therefore be best to 
consider the data presented in this thesis as preliminary data, and to weight the 
conclusions of Lin, et al. (53) more heavily. 
 However, if we assume that site directed spin labeling at S54C and T220C 
disturbed neither the structure nor function of the UtrABD1, then other explanations 
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should be considered. The choice of labeling sites is especially important. Lin, et al. (53) 
chose to label at V136C and L222C, since the distance between these residues predicted 
by each model produced significantly different simulated DEER waveforms, and since 
each predicted distance was well within the range detectable by either DEER or CW-
EPR. However, the choice of V136C places a label close the interface between CH 
domains in the closed model. Although it is possible to model MSL into the crystal 
structure of UtrABD1 at V136C without producing steric clashes, in solution the spin 
label may adopt a conformation which would favor an opening of the UtrABD1. 
 Based on this concern, Roberto Dominguez and colleagues designed the 
S54C/T220C labeling sites. This pair of labeling sites places the spin labels on the 
exterior of the protein, based on both closed and open models. However, the C-C 
distance between residues 54 and 220 is 6.4 nm in x-ray crystal protomer, and 7.7 nm in 
the open EM model. Although these distances are within the theoretical detection limits 
of DEER, they lay outside the range of what can be reliably detected in difficult samples 
– such as those containing a high concentration of F-actin. In such samples, the practical 
upper limit for detection by DEER becomes ~5 nm (56). Additionally, the distance 
between radicals on the actual spin labels may be even greater, depending on the 
conformation adopted by the labels relative to UtrABD1.  
 Thus, we have data from two different sets of labeling sites, each of which is 
imperfect. The sites chosen by Lin, et al. (53) may favor the detection of an open 
conformation, whereas S54C/T220C may fail to accurately detect an open conformation. 
In order to resolve the discrepancy between these two datasets, it may therefore be 
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necessary to design new labeling sites. These sites should be within the dynamic range of 
DEER for actin-bound samples as per Lin, et al. (53), but should also be designed using 
tools such as molecular dynamics simulations to avoid sites where the spin label itself 
might favor a conformational change in the larger protein construct. 
 Alternatively, these datasets may not truly be in conflict. By performing rigid body 
rotations about the residue 149/150 peptide bond, Lin, et al. (53) computationally 
generated  a set of at least 21 models of UtrABD1 which satisfied the constraint of a 4.8 
nm distance between V136C/L222C, as measured by DEER in the presence of saturating 
F-actin. Comparing these models visually, by holding one CH domain fixed in the space, 
it can be seen that the other CH domain rotates about the axis of the UtrABD1 with 
regard to the first.  
 Therefore, an opening of the UtrABD1 might be accompanied by a rotation of the 
CH domains relative to one another. This rotation might either enhance or mitigate an 
increase in distance due to the larger scale opening of the UtrABD1. In this way, we 
might see an increase in distance between V136C and L222C upon binding to actin (as 
measured by Lin, et al.), but little change in the distance between S54C and T220C (as 
seen in Fig. 5). Conversely, a modest opening of the UtrABD1 accompanied by a rotation 
of the CH domains relative to one another could also produce this pattern. Orientation 
information derived from continuous wave EPR will be necessary in order to resolve 
ambiguity introduced by the possibility of the rotation of the CH domains (61). 
 In either case, UtrABD1 likely occupies a novel conformation seen in neither the x-
ray crystal nor modeled based on electron microscopy, both when free in solution and 
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bound to actin. Such a conformation might nonetheless be substantially similar to those 
modeled previously, but would incorporate a rotation of the CH domains relative to one 
another as compared to either the x-ray crystal or one of the EM models. 
2.4.2 | Does the dystrophin ABD1 bind actin in a closed conformation? 
 DysABD1 appears to exist in equilibrium between two conformations. The bulk of 
the population (~65%) occupies a conformation such that the distance between spin 
labels at D38C and C205 is 2.5 nm, in close agreement with the 2.4 nm predicted by the 
closed EM structure (Fig. 7) (52). The remaining third of the population occupies a 
somewhat more extended and disordered conformation, with an average distance between 
labels at D38C/C205 of ~3.5 nm. Unlike UtrABD1, interpretation of the DEER 
waveforms did not change significantly depending on the method of background 
subtraction. Notably, the spectra did not change significantly even with the addition of a 
four-fold molar excess of F-actin (Fig. 7J, M). 
 As with UtrABD1, several caveats apply. The requisite controls have not been 
carried out, and therefore this data must be considered preliminary. In order to determine 
that site direct spin labeling did not disturb the function of DysABD1, actin co-
sedimentation experiments must still be carried out. In addition, circular dichroism 
measurements also need to be made, in order to ensure labeling did not perturb the 
secondary structure of DysABD1.  
 Interpretation of the data with respect to the actin-bound conformation of 
DysABD1 is especially difficult. The lack of an increase in the distance measured by 
DEER as F-actin was added in increasing amounts may indicate that DysABD1 does not 
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change conformation upon binding to actin. However, in the absence of co-sedimentation 
data, it may be that spin labeling is preventing DysABD1 from binding to actin. If 
DysABD1 adopts a closed conformation in solution, but is being prevented from binding 
to actin by the spin labels, then we would continue to detect a closed conformation even 
as actin is added to the sample. 
 The significance of the 2-Gaussian distribution must similarly be interpreted with 
caution, especially since the 3.5 nm distance is not predicted by any previous model of 
DysABD1. Although DysABD1 may be interconverting between two primary 
conformations, it is also possible that the spin label at either residue 38 or 205 is not 
isotropically sampling all possible angles with respect to DysABD1. In the latter case, the 
detection of multiple distances might reflect the conformational selection of the spin 
label. Molecular dynamics simulations would be useful in distinguishing between these 
two possibilities.  
2.4.3 | Concluding Thoughts 
 Although further controls are necessary, it is likely that UtrABD1 binds to actin in a 
conformation not previously modeled. Given the homology between the two domains, the 
same may apply to DysABD1. In order to build accurate models of UtrABD1 and 
DysABD1, a number of techniques yielding complementary structural data should be 
combined. 
 By designing novel labeling sites, further DEER experiments can provide 
additional distance information. Similar information could also be derived from 
fluorescence resonance energy transfer (FRET) experiments using fluorescently labeled 
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UtrABD1 and DysABD1 (62, 63). FRET provides the additional advantage of working in 
solution at physiological temperatures, as opposed to the cryogenic temperatures required 
for DEER, and at lower protein concentrations. By placing fluorescent probes at the same 
labeling sites, FRET can therefore be used to corroborate measurements made by DEER. 
 With respect to the actin-bound state, conventional EPR can provide information 
about the angle of a given spin labeled site with regard to the filament (61). Finger 
printing experiments, such as hydrogen/deuterium exchange or hydroxyl radical foot 
printing coupled to mass spectrometry, can provide information about the solvent 
accessibility of either the protein backbone or side chains, and can suggest residues likely 
to interact with F-actin (64, 65). Nuclear magnetic resonance (NMR) techniques would 
be difficult to apply to the actin-bound ABD1s, but could be used to study UtrABD1 and 
DysABD1 free in solution. Additionally, certain NMR techniques may be able to provide 
spare structural information about the actin-bound ABD1 (66-69). 
 With enough such information to act as constraints, it will be possible to 
computationally model UtrABD1 and DysABD1. Especially if done for both the free and 
actin-bound states, such models might prove useful in engineering improved ABD1s for 
use in gene therapy.  
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